Antibiotic Batumin as the Ukrainian Effective Staphylococci Fighter

2005, Microbiology

December 1, 2005, in Ukraine there was held a strategically important for modern medicine event, where there was presented the new antibiotic batumin, which is a common development of the Ukrainian and Belgian scientists.

According to specialists, this antibiotic may be a kind of the medical “superpenitsylinom” that can successfully combat infectious diseases, primarily caused by S. aureus, which kills thousands of people worldwide every year.

The new high-staphylococci antibiotic batumin was isolated from the new species "Pseudomonas batumici" at the Institute of Microbiology and Virology of the National Academy of Sciences of Ukraine. The research lasted for 30 years.

The crucial achievement includes the fact that batumin acts on all types of staphylococci, even those that are not killed by other drugs. The chemical structure of the antibiotic is already established as the result of numerous investigations. In its chemical structure, it has no analogs among antibiotics that are used in practical medicine, so that’s a unique medical development.

Batumin has a unique selective activity for all studied staphylococcal species and shows moderate activity in relation to the representatives of other taxonomic groups.

Although the new antibiotic is the invention of scientists of the Research Institute of Microbiology and Virology of the National Academy of Sciences named after D.K. Zabolotny, Belgian scientists also made a great contribution to successful research and joined to its perfection in order to turn into a therapeutic means of mass application.

Moreover, Belgian scientists are proud of the fact that they took part in such a great medical research together with the Ukrainian scientists and accentuate that it is important that batumin is the world number one means that effectively destroys staphylococci, which has already become accustomed to traditional therapeutic drugs.

December 2, 2005, the license agreement was signed between the Institute of Microbiology and Virology of National Academy of Sciences of Ukraine and Belgian company “Reseda”. Investing in this project, which is international in scope, has become an important source of revenue for the budget of Ukraine.